Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities – Biotech Investments
Issuer: CureVac / Key word(s): Restructure of Company/Strategic Company Decision 03.07.2024 / 08:12 CET/CEST The issuer is solely responsible for the content of this announcement.